Business
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the
About this update from Rain Enhancement Technologies Holdco, Inc.
NEWARK, Calif. , July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023 . On that day, management will host a conference call and webcast at 2:00 pm PT ( 5:00 pm ET ) to discuss the Company’s business and financial results. Conference Call and Webcast Details: Date: August 10, 2023 Time: 2:00 pm PT ( 5:00 pm ET )Dial In Numbers: 1 (888) 886-7786 ( U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the call will be available by visiting the " Events " section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. Media Contact Mahima Agochiya Rain Oncology [email protected] Investor Contact Dan Ferry LifeSci Advisors +1.617.430.7576 [email protected] Source: Rain Oncology Inc.
View stock analysis, news, and events for Rain Enhancement Technologies Holdco, Inc.